More questions regarding HIPEC in colorectal carcinomatosis
Mené sur 204 patients atteints d'un cancer du côlon de stade localement avancé (âge : de 18 à 75 ans), cet essai multicentrique randomisé évalue, du point de vue de la survie sans métastase péritonéale à 18 mois, l'intérêt d'ajouter une chimiothérapie hyperthermique intrapéritonéale à une chimiothérapie adjuvante systémique
In The Lancet Gastroenterology & Hepatology, Charlotte Klaver and colleagues report the highly anticipated COLOPEC trial, the first study to assess the benefits of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) followed by adjuvant systemic chemotherapy, compared with adjuvant systemic chemotherapy alone, for patients with high-risk colorectal cancer (clinical or pathological T4N0–2M0-stage tumours). Historically, nearly 20% of patients with locally advanced colorectal cancer have metachronous peritoneal metastases. These patients have significantly worse overall survival than those with liver or lung involvement. Therefore, the need for novel approaches in patients with the highest risk for developing peritoneal metastasis remains unmet and we congratulate the authors for designing this trial.
The Lancet Gastroenterology & Hepatology , commentaire, 2018